Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 81,700 KRW
Change Today +2,100 / 2.64%
Volume 505.3K
As of 2:27 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

sk chemicals co ltd (006120) Snapshot

Open
79,600
Previous Close
79,600
Day High
85,400
Day Low
79,000
52 Week High
05/29/15 - 85,400
52 Week Low
10/16/14 - 55,000
Market Cap
1.7T
Average Volume 10 Days
412.5K
EPS TTM
-1,392.00
Shares Outstanding
20.8M
EX-Date
12/29/14
P/E TM
--
Dividend
300.00
Dividend Yield
0.37%
Current Stock Chart for SK CHEMICALS CO LTD (006120)

Related News

No related news articles were found.

sk chemicals co ltd (006120) Related Businessweek News

No Related Businessweek News Found

sk chemicals co ltd (006120) Details

SK Chemicals Co., Ltd. is engaged in chemical and life science businesses in Korea and internationally. The company provides copolyester comprising bio copolyester products under the ECOZEN name; SKYGREEN PETG resins; and polyethylene terephthalate resins under the SKYPET name. It also offers polyester resins for the use in coil and can coating under the SKYBON name; chemicals, reagents, and solvents that are used in laboratory research, electric/electronics, and bio-technology industry under the CnR name; chemicals, such as optical materials for display technology and electrolytes for supercapacitors; and acoustic insulations under the SKYVIVA name. In addition, the company provides non-hazardous sound absorbing/proofing material for automotive applications under the SKYNOVA name; sheet materials under the SKYFLEX name; and engineering plastic products under the SK COMPOUND and ECOTRAN names. Further, it offers biomaterial products comprising biodiesel under the ECOPRIME name; and polylactic acid biomaterial products under the ECOPLAN name. Additionally, the company provides prescription medicines primarily for fibrous tumors, prostates, endometriosis, and diabetes diseases; OTC products for blood circulation, anti-inflammatory and analgesic actions, arthritis, muscle pain, and bruises; and medical IT solutions. It also offers vaccines for hepatitis B; chickenpox; diphtheria, tetanus, and pertussis; polio; measles, mumps, and rubella; tetanus and diphtheria; and eningitis and influenza, as well as operates in consulting, polyester adhesives manufacturing, pharmaceutical marketing, and plastic material wholesale businesses. SK Chemicals Co., Ltd. was founded in 1969 and is headquartered in Seongnam, South Korea.

Founded in 1969

sk chemicals co ltd (006120) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sk chemicals co ltd (006120) Key Developments

SK Chemicals Co.,Ltd. Appoints Han Byeong-Ro as New CEO

SK Chemicals Co Ltd. has appointed Han Byeong-ro, current vice-president, as new CEO. Previously, Vice-President Han Byeong-ro used his extensive experience in finance, HR and labor management to stabilize labor-management relations and promote the global expansion of the Life Science Business. Along with his duties as CEO of Life Science Biz in charge of pharmaceutical operations, Mr. Han will also serve as COO (COO), oversee marketing and business support sections, and assist President Park Man-hoon. This will allow President Park, who took up his post early this year, to direct all management and fulfill his role as CTO (Chief Technology Officer), which entails focusing on R&D and production for the continued growth of core businesses including vaccines.

SK Chemicals Co.,Ltd, Annual General Meeting, Mar 20, 2015

SK Chemicals Co.,Ltd, Annual General Meeting, Mar 20, 2015., at 09:00 Korea Standard Time. Location: SK Chemicals B / D 2 underground floors G.rium Hall. Agenda: To consider financial statements, the consolidated financial statements, audit reports and sales reports; to consider election of directors; to consider appointment of outside directors; to appointment of audit committee; and to consider approval of director remuneration.

Sanofi Pasteur SA Partners with SK Chemicals Ltd to Co-Develop Pneumococcal Conjugate Vaccine

Sanofi Pasteur SA has signed an agreement with SK Chemicals Co. Ltd., to co-develop a pneumococcal conjugate vaccine. The collaboration agreement includes research and development, production and commercialization of a preventative pneumococcal disease vaccine. As part of the agreement, Sanofi will make an up-front payment of $23 million to SK Chemicals. Both companies will co-invest in the development of the PCV vaccine project and, if successful, SK Chemicals would produce the vaccine at its production facility located in An-dong--the southern part of Korea. The product, once registered, will be launched globally by Sanofi Pasteur with shared profits outside of Korea, where SK Chemicals would commercialize it with exclusive rights.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
006120:KS 81,700.00 KRW +2,100

006120 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celanese Corp $68.85 USD +0.21
Daicel Corp ¥1,619 JPY +5.00
Hangzhou First Pv Material Co Ltd CNY57.08 CNY 0.00
Mitsui Chemicals Inc ¥406.00 JPY +1.00
STR Holdings Inc $1.11 USD -0.02
View Industry Companies
 

Industry Analysis

006120

Industry Average

Valuation 006120 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 1.4x
Price/Cash Flow 479.0x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SK CHEMICALS CO LTD, please visit www.skchemicals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.